Cargando…

Current trials in erythropoietic protoporphyria: are placebo controls ethical?

A new active substance called “dersimelagon” (MT-7117) is being tested as an alternative treatment option for Erythropoietic protoporphyria (EPP). At the moment, dersimelagon is being tested both in the US and in Europe in a phase III placebo-controlled RCT. However, given the availability of an alr...

Descripción completa

Detalles Bibliográficos
Autores principales: Barman-Aksözen, Jasmin, Andreoletti, Mattia, Blasimme, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10580501/
https://www.ncbi.nlm.nih.gov/pubmed/37845740
http://dx.doi.org/10.1186/s13023-023-02941-w